UniProt Q9Y3S1 · PDB · AlphaFold · Substrate: MBP · Clone: Catalytic (166-489)
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Neratinib | 47.2% | 52.8% | 93.18 | 0.597 |
| 2 | Pacritinib | 35.4% | 64.6% | 88.64 | 0.452 |
| 3 | Vemurafenib | 34.7% | 65.3% | 96.49 | 0.598 |
| 4 | Bosutinib | 34.1% | 65.9% | 87.22 | 0.555 |
| 5 | Alectinib | 13.3% | 86.7% | 95.49 | 0.651 |
| 6 | Dasatinib | 13.3% | 86.7% | 87.97 | 0.699 |
| 7 | Ceritinib | 10.1% | 89.9% | 95.44 | 0.618 |
| 8 | Leniolisib | 10.1% | 89.9% | 100.00 | 0.604 |
| 9 | Cabozantinib | 8.6% | 91.4% | 92.73 | 0.751 |
| 10 | Pazopanib | 8.6% | 91.4% | 97.49 | 0.672 |
| 11 | Gefitinib | 8.4% | 91.6% | 99.25 | 0.650 |
| 12 | Sunitinib | 8.2% | 91.8% | 91.73 | 0.524 |
| 13 | Sirolimus | 8.1% | 91.9% | 100.00 | 0.708 |
| 14 | Selumetinib | 7.9% | 92.1% | 100.00 | 0.640 |
| 15 | Tivozanib | 7.4% | 92.6% | 92.42 | 0.673 |
| 16 | Paxalisib | 7.0% | 93.0% | 99.75 | 0.609 |
| 17 | Pirtobrutinib | 6.7% | 93.3% | 99.49 | 0.656 |
| 18 | Lazertinib | 6.7% | 93.3% | 97.47 | 0.674 |
| 19 | Umbralisib | 6.6% | 93.4% | 98.74 | 0.670 |
| 20 | Gilteritinib | 6.2% | 93.8% | 88.97 | 0.506 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.48
- Epithelial log2(TPM+1): 3.11
- Fold change: -2.62
- Status: Downregulated
Selectivity landscape vs inhibition on WNK2
Each point is one of the 92 approved drugs; color = inhibition % on WNK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…